The Cannabis ETF
THCX
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- DE United States of America
- IPO Date
- Jul 9, 2019
- CIK
- 0001484018
- Similar Companies
- Business
- The Cannabis ETF (THCX) is an exchange-traded fund that provides investors with targeted exposure to the global cannabis industry through a portfolio of publicly traded equity securities. The fund tracks the THCX U.S. Cannabis Index, which includes companies involved in cannabis cultivation, production, distribution, and ancillary services such as pharmaceuticals, biotech, and retail; it emphasizes U.S.-based firms while also incorporating select international holdings in markets like Canada and Israel. THCX employs a modified equal-dollar weighted methodology to maintain diversification across approximately 25-35 holdings, rebalanced quarterly to reflect sector growth and compliance with evolving regulations. Launched in 2019 by Tuttle Capital Management, LLC, and listed on the NYSE Arca exchange, THCX is headquartered in New York, New York, and primarily serves institutional and retail investors seeking growth opportunities in the burgeoning cannabis and hemp sectors amid U.S. federal legalization progress and state-level expansions. The fund's assets under management fluctuate with market sentiment but have grown significantly following key catalysts like the 2024 U.S. Farm Bill amendments facilitating interstate commerce and banking reforms via the SAFE Banking Act passage. Recent strategic developments include a 2025 partnership with leading cannabis analytics provider New Frontier Data to enhance index methodology with real-time ESG and compliance metrics; an acquisition of exposure to emerging psychedelic therapeutics firms post-FDA breakthrough designations; and a product evolution with the launch of leveraged THCX options contracts in Q3 2025 to attract sophisticated traders. Geographically, THCX's portfolio spans North America, Europe, and Asia-Pacific, targeting multi-state operators (MSOs), craft growers, and technology enablers navigating regulatory shifts under the current Trump administration's pro-industry stance.